IOVS Journal of Nutrition
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2004;45:2075-2082.)
© 2004 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.03-1196
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by All-Ericsson, C.
Right arrow Articles by Larsson, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by All-Ericsson, C.
Right arrow Articles by Larsson, O.

c-Kit–Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target?

Charlotta All-Ericsson,1,2 Leonard Girnita,2,3 Anja Müller-Brunotte,1 Bertha Brodin,3 Stefan Seregard,1 Arne Östman,4 and Olle Larsson3

1From St. Erik’s Eye Hospital, Stockholm, Sweden; 3Cellular and Molecular Tumor Pathology, Department of Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; and the 4Ludwig Institute for Cancer Research, Uppsala, Sweden.

PURPOSE. This study was conducted to investigate the expression and functional impact of the proto-oncogene c-kit in uveal melanoma.

METHODS. Based on immunohistochemical (IHC) study of paraffin-embedded specimens from 134 uveal melanomas and Western blot analysis on eight fresh-frozen samples the expression of c-kit in uveal melanoma was studied. Furthermore, the phosphorylation of c-kit and the impact of the tyrosine kinase inhibitor STI571 was examined in the three uveal melanoma cell lines OCM-1, OCM-3, and 92–1.

RESULTS. Eighty-four of 134 paraffin-embedded samples and six of eight fresh-frozen samples expressed c-kit. c-Kit was strongly expressed and tyrosine phosphorylated in cultured uveal melanoma cells compared with cutaneous melanoma cells. Moreover, in contrast to cutaneous melanoma cell lines c-kit maintained a high phosphorylation level in serum-depleted uveal melanoma cells. No activation-related mutations in exon 11 of the KIT gene were found. On the contrary, expression of the stem cell growth factor (c-kit ligand) was detected in all three uveal melanoma cell lines, suggesting the presence of autocrine (paracrine) stimulation pathways. Treatment of uveal melanoma cell lines with STI571, which blocks c-kit autophosphorylation, resulted in cell death. The IC50 of the inhibitory effects on c-kit phosphorylation and cell proliferation was of equal size and less than 2.5 µM.

CONCLUSIONS. The results confirm that c-kit is vastly expressed in uveal melanoma, suggest that the c-kit molecular pathway may be important in uveal melanoma growth, and point to its use as a target for therapy with STI571.




This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
A. B. Daniels and D. H. Abramson
c-KIT in Uveal Melanoma: Big Fish or Red Herring?
Arch Ophthalmol, May 1, 2009; 127(5): 695 - 697.
[Full Text] [PDF]

Home page
 IOVSHome page
G. Lefevre, N. Babchia, A. Calipel, F. Mouriaux, A.-M. Faussat, S. Mrzyk, and F. Mascarelli
Activation of the FGF2/FGFR1 Autocrine Loop for Cell Proliferation and Survival in Uveal Melanoma Cells
Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1047 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. B. Hofmann, C. S. Kauczok-Vetter, R. Houben, and J. C. Becker
Overexpression of the KIT/SCF in Uveal Melanoma Does Not Translate into Clinical Efficacy of Imatinib Mesylate
Clin. Cancer Res., January 1, 2009; 15(1): 324 - 329.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. A. Economou, S. Andersson, D. Vasilcanu, C. All-Ericsson, E. Menu, A. Girnita, L. Girnita, M. Axelson, S. Seregard, and O. Larsson
Oral Picropodophyllin (PPP) Is Well Tolerated In Vivo and Inhibits IGF-1R Expression and Growth of Uveal Melanoma
Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2337 - 2342.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
R. J Barry, L. R de Moura, J.-C. Marshall, B. F Fernandes, M. E. Orellana, E. Antecka, C. Martins, and M. N Burnier
Expression of C-kit in retinoblastoma: a potential therapeutic target
Br. J. Ophthalmol., November 1, 2007; 91(11): 1532 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Strumberg, J. W. Clark, A. Awada, M. J. Moore, H. Richly, A. Hendlisz, H. W. Hirte, J. P. Eder, H.-J. Lenz, and B. Schwartz
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors
Oncologist, April 1, 2007; 12(4): 426 - 437.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. A. Economou, C. All-Ericsson, V. Bykov, L. Girnita, A. Bartolazzi, O. Larsson, and S. Seregard
Receptors for the Liver Synthesized Growth Factors IGF-1 and HGF/SF in Uveal Melanoma: Intercorrelation and Prognostic Implications
Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4372 - 4375.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Association for Research in Vision and Ophthalmology